BioCentury
ARTICLE | Company News

Therapeia, Telix deal

February 3, 2017 9:20 PM UTC

Therapeia granted Telix rights to ACD-101 to treat glioblastoma and an exclusive option to acquire Therapeia, which Telix plans to exercise in 2Q17. Telix said it expects the synthetic amino acid that...